Who
Frank McCormick
Director
Company insider
Files Form 4 as: Chairman of Oncology, BridgeBio Pharma; Director, BridgeBio Oncology Therapeutics; Director, Olema Pharmaceuticals; Director, Aduro Biotech; Director, Exelixis.
In numbers
- Trades disclosed
- 72
- Buys
- 0
- Sells
- 8
- Bought
- $0
- Sold
- $33.9M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 2 May 2006
- Last trade
- 22 Jun 2026
- Last filed
- 24 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —5,277 at $0.00 | filing |
| 22 Jun 2026filed 24 Jun 2026 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —3,990 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,675 at $0.00 | filing |
| 16 Jun 2026filed 18 Jun 2026 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —31,675 at $0.00 | filing |
| 29 Oct 2025filed 31 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $7.3M111,755 at $65.48 | filing |
| 29 Oct 2025filed 31 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $2.1M31,116 at $66.20 | filing |
| 29 Oct 2025filed 31 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $236K3,497 at $67.52 | filing |
| 29 Oct 2025filed 31 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $589K8,598 at $68.50 | filing |
| 29 Oct 2025filed 31 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $3.0M43,393 at $69.24 | filing |
| 27 Oct 2025filed 29 Oct 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $107K1,641 at $65.00 | filing |
| 5 Sep 2025filed 8 Sep 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code M | —74,000 at $0.00 | filing |
| 5 Sep 2025filed 8 Sep 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code M | $882K74,000 at $11.92 | filing |
| 5 Sep 2025filed 8 Sep 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $3.9M74,000 at $53.16 | filing |
| 26 Aug 2025filed 28 Aug 2025 | BBOT BridgeBio Oncology Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —91,076 at $0.00 | filing |
| 24 Jun 2025filed 26 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Sold | $4.4M100,000 at $44.23 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio Pharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —8,425 at $0.00 | filing |
| 20 Jun 2025filed 24 Jun 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code A | —6,589 at $0.00 | filing |
| 8 May 2025filed 9 May 2025 | BBIO BridgeBio PharmaBiotechnology | SEC FORM 4 Code G | —3,000 at $0.00 | filing |
News
BridgeBio Pharma (NASDAQ:BBIO) Given New $91.00 Price Target at CitigroupBBIO · dailypolitical.com · 19 Oct 2026
0 headlines in the last 90 days name Frank McCormick; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.